Conversion to everolimus in maintenance patients—current clinical strategies

Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function.

We present the 12-month results of a prospective trial of conversion from calcineurin inhibitors (CNI) to everolimus (EVL) in maintenance liver transplant (LT) recipients. Forty (M:F = 28:12; 54.9 +/- 11 years) patients were enrolled at a mean interval of 45.5 +/- 31.2 months from transplantation. Conversion was with EVL at a dosage of 0.75 mg b.i.d., withdrawal of antimetabolites, and a 50%-pe...

Tacrolimus-Induced Salt Losing Nephropathy Resolved After Conversion to Everolimus

T is one of the most commonly used immunosuppressive drugs but tacrolimus-induced severe symptomatic hyponatremia is not a well-documented issue in kidney transplant patients. In our current report, we describe a case of tacrolimus-induced hyponatremia in a living donor kidney recipient in whom any other potential cause of hyponatremia was excluded, and tacrolimus-induced salt losing nephropath...

Conversion to Supported Employment: Initiatives and Strategies

Strategies for Studying Maintenance

Phase 1: Study a significant number of maintainers to thoroughly understand the nature of their work. This paper investigates the questions to ask in such a study. A companion paper [1] discusses some methods by which the questions can be answered. Phase 2: Develop and evaluate tools to help the maintainers work better. This work will be based on what we learn from phase 1, as well as ongoing i...

CCR Drug Updates Clinical Cancer Research Everolimus

Author's Institute, N Correspon The Resea Drive, Colu E-mail: Pet